F
Francesca Toffalorio
Researcher at European Institute of Oncology
Publications - 42
Citations - 1133
Francesca Toffalorio is an academic researcher from European Institute of Oncology. The author has contributed to research in topics: Lung cancer & Crizotinib. The author has an hindex of 16, co-authored 36 publications receiving 943 citations. Previous affiliations of Francesca Toffalorio include Hoffmann-La Roche.
Papers
More filters
Journal ArticleDOI
Breast phyllodes tumor: A review of literature and a single center retrospective series analysis
Gianluca Spitaleri,Antonio Toesca,Edoardo Botteri,Luca Bottiglieri,Nicole Rotmensz,S. Boselli,Claudia Sangalli,Chiara Catania,Francesca Toffalorio,Cristina Noberasco,Angelo Delmonte,Alberto Luini,Paolo Veronesi,Paolo Veronesi,Marco Colleoni,Giuseppe Viale,Giuseppe Viale,Stefano Zurrida,Stefano Zurrida,Aron Goldhirsch,Umberto Veronesi,Tommaso De Pas +21 more
TL;DR: Prognosis of phyllodes tumors is excellent, and there are no convincing data to recommend any adjuvant treatment after surgery, but molecular characterization may well provide new clues to permit identification of active treatments for the rare poor prognosis cases.
Book ChapterDOI
TRIM proteins in cancer.
Valeria Cambiaghi,Virginia Giuliani,Sara Lombardi,Cristiano Marinelli,Francesca Toffalorio,Pier Giuseppe Pelicci,Pier Giuseppe Pelicci +6 more
TL;DR: The biological functions of TRIM proteins in cancer are discussed, with members of the TRIM family linked to cancer development without being involved in chromosomal re-arrangements, possibly through ubiquitination or loss of tumour suppression functions.
Journal ArticleDOI
Activity of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients with Non-small Cell Lung Cancer Harboring Rare Epidermal Growth Factor Receptor Mutations
Tommaso De Pas,Francesca Toffalorio,Michela Manzotti,Caterina Fumagalli,Gianluca Spitaleri,Chiara Catania,Angelo Delmonte,M. Giovannini,Lorenzo Spaggiari,Filippo de Braud,Massimo Barberis +10 more
TL;DR: Gefitinib and erlotinib have different antitumor activity according to the type of the EGFR mutation borne, and report of cases harboring rare mutations can support the decision-making process in this subset of patients.
Journal ArticleDOI
Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy
Paolo Andrea Zucali,Tommaso De Pas,Giovannella Palmieri,Adolfo Favaretto,Antonio Chella,Marcello Tiseo,Michele Caruso,Matteo Simonelli,Matteo Perrino,Fabio De Vincenzo,Francesca Toffalorio,Vincenzo Damiano,Giulia Pasello,Erika Garbella,M. Ali,Fabio Conforti,Margaret Ottaviano,Angela Cioffi,Sabino De Placido,Laura Giordano,Monica Bertossi,Annarita Destro,Luca Di Tommaso,Armando Santoro +23 more
TL;DR: Everolimus may induce durable disease control in a high percentage of patients with T or TC, albeit with a potential high risk of fatal pneumonitis, as evaluated in a single-arm, single-stage, open-label, multicenter, phase II trial.